Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000048073
JPRN-UMIN000048073
Not yet recruiting
未知

A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Resection for Hepato-Pancreato-Biliary Surgeries. - RENUH trial

Keio University0 sites60 target enrollmentJune 20, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHBP malignancies (major hepatectomy, pancreatoduodenectomy)

Overview

Phase
未知
Intervention
Not specified
Conditions
HBP malignancies (major hepatectomy, pancreatoduodenectomy)
Sponsor
Keio University
Enrollment
60
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 20, 2022
End Date
March 31, 2024
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •The patients who have uncontrollable infection, diabetes, cerebral infarction, and myocardial infarction.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Canceresophageal cancer
JPRN-UMIN000045479Keio University33
Recruiting
Not Applicable
Clinical study to determine the appropriateness of a starting dose of 160 mg/day of lazertinib in patients with EGFR T790M-positive non-small cell lung cancerNeoplasms
KCT0008332Samsung Medical Center117
Not yet recruiting
Phase 2
Dose-Dense ABVD Study: An accelerated delivery of Adriamycin, Bleomycin, Vinblastin and Dacarbazine for patients with Hodgkin LymphomaEarly Stage Unfavourable Hodgkin LymphomaAdvanced Stage Hodgkin LymphomaCancer - Hodgkin's
ACTRN12612000137897Queensland Health31
Active, not recruiting
Phase 1
A Study of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA SignalingSolid Tumors Dependent on KIT or PDGFRA SignalingMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2020-005234-15-ITBLUEPRINT MEDICINES CORPORATIO37
Active, not recruiting
Phase 1
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
CTIS2023-508617-16-00Blueprint Medicines Corp.37